Clinical trials of intranasal delivery for treating neurological disorders a critical review

Expert Opinion on Drug Delivery

Volumn 8, Issue 12, 2011, Pages 1681-1690

  Liu, Xinfeng ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Clinical trials; Insulin; Intranasal delivery; Neurological disorders; Orexin A; Oxytocin

Indexed keywords

APOLIPOPROTEIN E; ARGIPRESSIN; CHOLECYSTOKININ; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HYDROXOCOBALAMIN; INSULIN; MELANOCORTIN; MELATONIN; NEUROPEPTIDE Y; NEUROTROPHIC FACTOR; OREXIN A; OXYTOCIN; PERILLYL ALCOHOL; VASOPRESSIN;

ALZHEIMER DISEASE; ANXIETY DISORDER; APHASIA; ATTENTION; AUTISM; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID; CHROMOSOME DELETION 22Q11; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DECLARATIVE MEMORY; DEMENTIA; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG TOLERABILITY; ELECTROENCEPHALOGRAM; EMPATHY; EVENT RELATED POTENTIAL; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GAZE; GLIOBLASTOMA; HUMAN; HYPOGLYCEMIA; INTRANASAL DRUG ADMINISTRATION; LEARNING; MEMORY; MILD COGNITIVE IMPAIRMENT; MOOD; MOOD DISORDER; NARCOLEPSY; NEUROLOGIC DISEASE; NONHUMAN; OBESITY; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PICK PRESENILE DEMENTIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SINGLE DRUG DOSE; SOCIAL BEHAVIOR; SOCIAL PHOBIA; STROKE; TRAUMATIC BRAIN INJURY; TREATMENT DURATION; TRUST; TUMOR VOLUME;

ADMINISTRATION, INTRANASAL; ANIMALS; CENTRAL NERVOUS SYSTEM AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; NERVOUS SYSTEM DISEASES;

EID: 81855167454     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2011.633508     Document Type: Review

References (86)

1. Chinese Pharmacopoeia. Chemical Industry Press; Beijing: 2005
2. Fousteri G, Chan JR, Zheng Y, et al. Virtual optimization of nasal insulin therapy predicts immunization frequency to be crucial for diabetes protection. Diabetes 2010;59:3148-58
3. Law S, Derry S and Moore RA. Triptans for acute cluster headache. Cochrane Database Syst Rev 2010;CD008042
4. Frey WH. Neurologic agents for nasal administration to the brain. Chiron Corporation; US: 1991
5. Pardridge WM. The blood-brain barrier: Bottleneck in brain drug development. Neuro Rx 2005;2:3-14 (Pubitemid 40128022)
6. Kern W, Peters A, Fruehwald-Schultes B, et al. Improving influence of insulin on cognitive functions in humans. Neuroendocrinology 2001;74:270-80 (Pubitemid 34701752)
7. Dahl R, Mygind N. Anatomy, physiology and function of the nasal cavities in health and disease. Adv Drug Deliv Rev 1998;29:3-12 (Pubitemid 28044084)
8. Liu XF, Fawcett JR, Thorne RG, et al. Intranasal administration of insulin-like growth factor-i bypasses the blood-brain barrier and protects against focal cerebral ischemic damage. J Neurol Sci 2001;187:91-7 (Pubitemid 32618661)
9. Pires A, Fortuna A, Alves G, et al. Intranasal drug delivery: How, why and what for? J Pharm Pharm Sci 2009;12:288-311
10. Ma YP, Ma MM, Ge S, et al. Intranasally delivered tgf-beta1 enters brain and regulates gene expressions of its receptors in rats. Brain Res Bull 2007;74:271-7 (Pubitemid 47285524)
11. Perl DP, Good PF. Uptake of aluminium into central nervous system along nasal-olfactory pathways. Lancet 1987;1:1028 (Pubitemid 17057868)
12. Bondier JR, Michel G, Propper A, et al. Harmful effects of cadmium on olfactory system in mice. Inhal Toxicol 2008;20:1169-77
13. Broberg EK, Peltoniemi J, Nygardas M, et al. Spread and replication of and immune response to gamma134.5-negative herpes simplex virus type 1 vectors in balb/c mice. J Virol 2004;78:13139-52 (Pubitemid 39507821)
14. Han IK, Kim MY, Byun HM, et al. Enhanced brain targeting efficiency of intranasally administered plasmid DNA: An alternative route for brain gene therapy. J Mol Med 2007;85:75-83 (Pubitemid 46020944)
15. Bitko V, Barik S. Nasal delivery of si RNA. Methods Mol Biol 2008;442:75-82
16. Frenkel D, Solomon B. Filamentous phage as vector-mediated antibody delivery to the brain. Proc Natl Acad Sci USA 2002;99:5675-9 (Pubitemid 34411609)
17. Jiang Y, Zhu J, Xu G, et al. Intranasal delivery of stem cells to the brain. Expert Opin Drug Deliv 2011;8:623-32
18. Oberdorster G, Elder A, Rinderknecht A. Nanoparticles and the brain: cause for concern? J Nanosci Nanotechnol 2009;9:4996-5007
19. Dhuria SV, Hanson LR, Frey WH II. Intranasal delivery to the central nervous system: Mechanisms and experimental considerations. J Pharm Sci 2010;99:1654-73
20. Jiang Y, Wei N, Lu T, et al. Intranasal brain-derived neurotrophic factor protects brain from ischemic insult via modulating local inflammation in rats. Neuroscience 2011;172:398-405
21. Danielyan L, Schafer R, von Ameln-Mayerhofer A, et al. Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease. Rejuvenation Res 2011;14:3-16
22. De Rosa R, Garcia AA, Braschi C, et al. Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in ad11 anti-NGF transgenic mice. Proc Natl Acad Sci USA 2005;102:3811-16 (Pubitemid 40360709)
23. Born J, Lange T, Kern W, et al. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 2002;5:514-16 (Pubitemid 34568991)
24. Porte D Jr, Woods SC. Regulation of food intake and body weight in insulin. Diabetologia 1981; March(Suppl 20):274-80 (Pubitemid 11159659)
25. Park CR, Seeley RJ, Craft S, et al. Intracerebroventricular insulin enhances memory in a passive-avoidance task. Physiol Behav 2000;68:509-14 (Pubitemid 30129236)
26. Francis GJ, Martinez JA, Liu WQ, et al. Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type 1 diabetic encephalopathy. Brain 2008;131:3311-34
27. Benedict C, Hallschmid M, Hatke A, et al. Intranasal insulin improves memory in humans. Psychoneuroendocrinology 2004;29:1326-34 (Pubitemid 39024358)
28. Hallschmid M, Benedict C, Schultes B, et al. Obese men respond to cognitive but not to catabolic brain insulin signaling. Int J Obes (Lond) 2008;32:275-82 (Pubitemid 351271786)
29. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 2004;3:169-78 (Pubitemid 38229951)
30. Benedict C, Frey WH II, Schioth HB, et al. Intranasal insulin as a therapeutic option in the treatment of cognitive impairments. Exp Gerontol 2011;46:112-15
31. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 12 Sep 2011 [Epub ahead ofprint] doi:10.1001/ archneurol.2011.233
32. Frey WH. Method for administering insulin to the brain. Chiron Corporation; US: 2001
33. Reger MA, Watson GS, Green PS, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008;70:440-8
34. Reger MA, Watson GS, Frey WH II, et al. Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by Apo E genotype. Neurobiol Aging 2006;27:451-8 (Pubitemid 43185331)
35. Watt JL, Olson IA, Johnston AW, et al. A familial pericentric inversion of chromosome 22 with a recombinant subject illustrating a 'pure' partial monosomy syndrome. J Med Genet 1985;22:283-7 (Pubitemid 15240348)
36. Schmidt H, Kern W, Giese R, et al. Intranasal insulin to improve developmental delay in children with 22q13 deletion syndrome: An exploratory clinical trial. J Med Genet 2009;46:217-22
37. Fan X, Copeland PM, Liu EY, et al. No effect of single-dose intranasal insulin treatment on verbal memory and sustained attention in patients with schizophrenia. J Clin Psychopharmacol 2011;31:231-4
38. Thompson R, Gupta S, Miller K, et al. The effects of vasopressin on human facial responses related to social communication. Psychoneuroendocrinology 2004;29:35-48 (Pubitemid 37303959)
39. Guastella AJ, Kenyon AR, Alvares GA, et al. Intranasal arginine vasopressin enhances the encoding of happy and angry faces in humans. Biol Psychiatry 2010;67:1220-2
40. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011;123:e18-209
41. Tsikunov SG, Belokoskova SG. Psychophysiological analysis of the influence of vasopressin on speech in patients with post-stroke aphasias. Span J Psychol 2007;10:178-88
42. Heinrichs M, Domes G. Neuropeptides and social behaviour: effects of oxytocin and vasopressin in humans. Prog Brain Res 2008;170:337-50 (Pubitemid 352010240)
43. Lim MM, Young LJ. Neuropeptidergic regulation of affiliative behavior and social bonding in animals. Horm Behav 2006;50:506-17 (Pubitemid 44307118)
44. Striepens N, Kendrick KM, Maier W, et al. Prosocial effects of oxytocin and clinical evidence for its therapeutic potential. Front Neuroendocrinol 2011;32:426-50
45. Kosfeld M, Heinrichs M, Zak PJ, et al. Oxytocin increases trust in humans. Nature 2005;435:673-6 (Pubitemid 40825511)
46. Domes G, Heinrichs M, Michel A, et al. Oxytocin improves "mind-reading" in humans. Biol Psychiatry 2007;61:731-3
47. Guastella AJ, Mitchell PB, Dadds MR Oxytocin increases gaze to the eye region of human faces. Biol Psychiatry 2008;63:3-5 (Pubitemid 350234895)
48. Domes G, Heinrichs M, Glascher J, et al. Oxytocin attenuates amygdala responses to emotional faces regardless of valence. Biol Psychiatry 2007;62:1187-90 (Pubitemid 350029722)
49. Baumgartner T, Heinrichs M, Vonlanthen A, et al. Oxytocin shapes the neural circuitry of trust and trust adaptation in humans. Neuron 2008;58:639-50 (Pubitemid 351672358)
50. Ditzen B, Schaer M, Gabriel B, et al. Intranasal oxytocin increases positive communication and reduces cortisol levels during couple conflict. Biol Psychiatry 2009;65:728-31
51. Guastella AJ, Howard AL, Dadds MR et al. A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology 2009;34:917-23
52. Labuschagne I, Phan KL, Wood A, et al. Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder. Neuropsychopharmacology 2010;35:2403-13
53. Guastella AJ, Einfeld SL, Gray KM, et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry 2010;67:692-4
54. Heinrichs M, Meinlschmidt G, Wippich W, et al. Selective amnesic effects of oxytocin on human memory. Physiol Behav 2004;83:31-8 (Pubitemid 39387691)
55. Savaskan E, Ehrhardt R, Schulz A, et al. Post-learning intranasal oxytocin modulates human memory for facial identity. Psychoneuroendocrinology 2008;33:368-74
56. Di Simplicio M, Massey-Chase R Cowen PJ, et al. Oxytocin enhances processing of positive versus negative emotional information in healthy male volunteers. J Psychopharmacol 2009;23:241-8
57. Rimmele U, Hediger K, Heinrichs M, et al. Oxytocin makes a face in memory familiar. J Neurosci 2009;29:38-42
58. Hurlemann R, Patin A, Onur OA, et al. Oxytocin enhances amygdala-dependent, socially reinforced learning and emotional empathy in humans. J Neurosci 2010;30:4999-5007
59. Perry A, Bentin S, Shalev I, et al. Intranasal oxytocin modulates EEG mu/alpha and beta rhythms during perception of biological motion. Psychoneuroendocrinology 2010;35:1446-53
60. Smeltzer MD, Curtis JT, Aragona BJ, et al. Dopamine, oxytocin, and vasopressin receptor binding in the medial prefrontal cortex of monogamous and promiscuous voles. Neurosci Lett 2006;394:146-51 (Pubitemid 43061477)
61. Caldwell HK, Stephens SL, Young WS III. Oxytocin as a natural antipsychotic: a study using oxytocin knockout mice. Mol Psychiatry 2009;14:190-6
62. Feifel D, Macdonald K, Nguyen A, et al. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol Psychiatry 2010;68:678-80
63. Belanger JT. Perillyl alcohol: applications in oncology. Altern Med Rev 1998;3:448-57 (Pubitemid 128709690)
64. Azzoli CG, Miller VA, Ng KK, et al. A phase I trial of perillyl alcohol in patients with advanced solid tumors. Cancer Chemother Pharmacol 2003;51:493-8 (Pubitemid 36791675)
65. da Fonseca CO, Schwartsmann G, Fischer J, et al. Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. Surg Neurol 2008;70:259-66; discussion 66-7
66. da Fonseca CO, Linden R, Futuro D, et al. Ras pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol. Arch Immunol Ther Exp (Warsz) 2008;56:267-76
67. Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci 2007;8:171-81 (Pubitemid 46294664)
68. Dhuria SV, Hanson LR, Frey WH II. Intranasal drug targeting of hypocretin-1 (orexin-a) to the central nervous system. J Pharm Sci 2009;98:2501-15
69. Deadwyler SA, Porrino L, Siegel JM, et al. Systemic and nasal delivery of orexin-A (hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci 2007;27:14239-47
70. Baier PC, Weinhold SL, Huth V, et al. Olfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal orexin A (hypocretin-1). Brain 2008;131:2734-41
71. Denecke H, Czehak N, Pietrowsky R. Dose-response relationships of intranasal cholecystokinin and the p300 event-related brain potential. Pharmacol Biochem Behav 2002;73:593-600 (Pubitemid 34876710)
72. Denecke H, Meyer F, Feldkamp J, et al. Repetitive intranasal administration of cholecystokinin potentiates its central nervous effects. Physiol Behav 2004;83:39-45 (Pubitemid 39387692)
73. Smolnik R, Fischer S, Hagenah J, et al. Brain potential signs of slowed stimulus processing following cholecystokinin in Parkinson's disease. Psychopharmacology (Berl) 2002;161:70-6 (Pubitemid 34437971)
74. Martinez JA, Francis GJ, Liu WQ, et al. Intranasal delivery of insulin and a nitric oxide synthase inhibitor in an experimental model of amyotrophic lateral sclerosis. Neuroscience 2008;157:908-25
75. Merkus P, Guchelaar HJ, Bosch DA et al. Direct access of drugs to the human brain after intranasal drug administration? Neurology 2003;60:1669-71 (Pubitemid 36618097)
76. van den Berg MP, Romeijn SG, Verhoef JC, et al. Serial cerebrospinal fluid sampling in a rat model to study drug uptake from the nasal cavity. J Neurosci Methods 2002;116:99-107 (Pubitemid 34465788)
77. Charlton ST, Davis SS, Illum L. Nasal administration of an angiotensin antagonist in the rat model: Effect of bioadhesive formulations on the distribution of drugs to the systemic and central nervous systems. Int J Pharm 2007;338:94-103 (Pubitemid 46783979)
78. Hallschmid M, Benedict C, Schultes B, et al. Towards the therapeutic use of intranasal neuropeptide administration in metabolic and cognitive disorders. Regul Pept 2008;149:79-83
79. Illum L. Nasal drug delivery-possibilities, problems and solutions. J Control Release 2003;87:187-98 (Pubitemid 36255456)
80. O'Collins VE, Macleod MR Donnan GA, et al. 1,026 experimental treatments in acute stroke. Ann Neurol 2006;59:467-77 (Pubitemid 43358067)
81. Fisher M, Feuerstein G, Howells DW, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009;40:2244-50
82. Contopoulos-Ioannidis DG, Ntzani E, Ioannidis JP. Translation of highly promising basic science research into clinical applications. Am J Med 2003;114:477-84 (Pubitemid 36515110)
83. Drolet BC, Lorenzi NM. Translational research: Understanding the continuum from bench to bedside. Transl Res 2011;157:1-5
84. Zerhouni EA. Translational and clinical science-time for a new vision. N Engl J Med 2005;353:1621-3 (Pubitemid 41434645)
85. Jiang Y, Wei N, Zhu J, et al. Effects of brain-derived neurotrophic factor on local inflammation in experimental stroke of rat. Mediators Inflamm 2010;2010:372423
86. Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein e in Alzheimer's disease and other neurological disorders. Lancet Neurol 2011;10:241-52